Sustime Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 22-12-2024
- Paid Up Capital ₹ 1.90 Cr
as on 22-12-2024
- Company Age 32 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 22-12-2024
- Satisfied Charges ₹ 4.68 M
as on 22-12-2024
- Revenue %
(FY 2022)
- Net Worth
- Total Assets %
(FY 2022)
About Sustime Pharma
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.90 Cr.
The company currently has active open charges totaling ₹5.00 M. The company has closed loans amounting to ₹4.68 M, as per Ministry of Corporate Affairs (MCA) records.
Sheela Bhogilal, Kaushik Shah, and Shivaji Patil serve as directors at the Company.
- CIN/LLPIN
U24230MH1992PLC065589
- Company No.
065589
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
25 Feb 1992
- Date of AGM
19 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sustime Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sheela Bhogilal  | Director | 25-May-1993 | Current |
| Kaushik Shah | Director | 08-Sep-2003 | Current |
| Shivaji Patil | Director | 21-Feb-2022 | Current |
Financial Performance of Sustime Pharma.
Sustime Pharma Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sustime Pharma?
In 2022, Sustime Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹0.50 Cr
₹0.47 Cr
Charges Breakdown by Lending Institutions
- Maharashtra State Financial Corp. : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Mar 1994 | Maharashtra State Financial Corp. | ₹5.00 M | Open |
| 17 Aug 1994 | The North Kanara G.B.B. Co-Op .Bank Ltd. | ₹2.48 M | Satisfied |
| 28 Jun 1994 | The North Kanara G.S.B. Co-Op Bank Ltd. | ₹2.20 M | Satisfied |
How Many Employees Work at Sustime Pharma?
Unlock and access historical data on people associated with Sustime Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sustime Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sustime Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
